News
14h
TipRanks on MSNAbbVie’s Promising Phase 3 Study on Upadacitinib for Alopecia AreataAbbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...
14h
TipRanks on MSNAbbVie and Genmab’s Promising Study on Epcoritamab for Non-Hodgkin LymphomaThe study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...
The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...
William Blair analysts project AbbVie to earn $16.15 per share by FY2028, a notable jump from its current $12.31 estimate.
AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results